Voyager Therapeutics, Inc. (VYGR) Fair Value 2026

VYGR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (49/100)

Quick Summary — As of 2026-08-28, Voyager Therapeutics, Inc. (VYGR) trades at $3.54. QOC: 6.2/10. Value Trap Risk: 49/100 (WARN). 1/13 models active.

Key Facts

Ticker
VYGR
Price
$3.54
Quality Score
6.2/10
Value Trap Risk
49/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 49 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give VYGR?

1 Intrinsic Value Models vs. Current Price ($3.54)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.88 -75.2%

All Models Active

All 1 models are displayed above.

What Is Voyager Therapeutics, Inc. (VYGR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Voyager Therapeutics, Inc.'s intrinsic value is estimated at $0.88. Trading at its current price of $3.54, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -75.2%.

What Do the Models Say About VYGR?

1 of 13 models are currently active for VYGR. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does VYGR Rank in Biotechnology?

Among 625 Biotechnology stocks, VYGR ranks #128 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Voyager Therapeutics, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is VYGR a Value Trap?

CirclFi's Value Trap algorithm assigns VYGR a score of 49/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Voyager Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Voyager Therapeutics, Inc. scores 6.2 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every VYGR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across VYGR's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Voyager Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MGNXMacroGenics, Inc.QOC 6.2CLDXCelldex Therapeutics, Inc.QOC 6.2ATHEAlterity Therapeutics LimitedQOC 6.2DTILPrecision BioSciences, Inc.QOC 6.2CRDFCardiff Oncology, Inc.QOC 6.2RNXTRenovoRx, Inc.QOC 6.1LGVNLongeveron Inc.QOC 5.1MLTXMoonLake ImmunotherapeuticsQOC 4.5ENLVEnlivex Ltd.QOC 3.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MGNX · CLDX · ATHE · DTIL · CRDF · RNXT · LGVN · MLTX · ENLV · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to VYGR?

7 companies across all industries closest to VYGR’s Quality of Company score of 6.2/10.

NWLNewell Brands Inc.QOC 6.2SSPThe E.W. Scripps CompanyQOC 6.2SYPRSypris Solutions, Inc.QOC 6.2VACMarriott Vacations Worldwide CorporationQOC 6.2SANGSangoma Technologies CorporationQOC 6.2CRVWCareView Communications, Inc.QOC 6.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NWL · SSP · SYPR · VAC · SANG · CRVW · NVDA

Where Does VYGR Sit in CirclFi's Biotechnology Rankings?

VYGR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Voyager Therapeutics, Inc.’s Valuation?

What is Voyager Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Voyager Therapeutics, Inc. (VYGR). The Quality of Company score is 6.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is VYGR overvalued or undervalued right now?

At $3.54, 0 of 1 active models suggest VYGR may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Voyager Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.2 mean for VYGR?

Voyager Therapeutics, Inc.'s QOC of 6.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on VYGR?

CirclFi analyzes VYGR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is VYGR a value trap in 2026?

Voyager Therapeutics, Inc.'s Value Trap score is 49/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Voyager Therapeutics, Inc. (VYGR) a Quality of Company score of 6.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/VYGR/ · Methodology
Primary sources for this VYGR valuation
  • Financial statements: Voyager Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001640266) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for VYGR as of ; valuations recomputed .